Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open (Partially Double-blind), Randomized, Controlled Dose-range Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Investigational Vaccination Regimens Versus MENINGITEC or MENCEVAX ACWY When Given as One Dose to Children Aged 12 to 14 Months and 3 to 5 Years Old.

Next Previous
Trial Profile

A Phase II, Open (Partially Double-blind), Randomized, Controlled Dose-range Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Investigational Vaccination Regimens Versus MENINGITEC or MENCEVAX ACWY When Given as One Dose to Children Aged 12 to 14 Months and 3 to 5 Years Old.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningitis; Meningococcal infections; Various toxicities
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 04 Oct 2011 Official Title amended as reported by ClinicalTrials.gov.
  • 16 Dec 2009 Results were published in Vaccine.
  • 07 Mar 2008 Status changed from in progress to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top